Clinical Trial Update: Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed [Phase 2]

View source ↗

Summary

A phase 2 trial of erlotinib for unresectable hepatocellular carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer | Phase 2 | Status: TERMINATED